Regulatory Affairs (RA) encompasses all strategic and operative activities used by companies to ensure that a medicinal product or medical device meets relevant legal requirements—from early development to post-market surveillance. Regulatory Affairs thus serves as an interface between Research & Development, Quality, Clinical Development, Pharmacovigilance, Production, and regulatory authorities. Without a sound regulatory strategy, even a scientifically compelling product can fail to meet regulatory requirements or face significant delays.
What does Regulatory Affairs do – and why is it so important?
The core mission of Regulatory Affairs is to translate regulatory requirements into concrete development and documentation steps. In practice, this means RA ensures that studies, dossiers, approval processes, and product changes are planned in a way that is regulatorily acceptable. Errors in this phase can lead to delays, additional studies, rejections, or compliance risks.
The framework is particularly complex in Europe: EU pharmaceutical law applies to medicinal products, specified by directives and regulations of the European Commission and EMA guidelines. For clinical trials, the EU Regulation CTR 536/2014 is decisive, while the EU MDR 2017/745 applies to medical devices. Regulatory Affairs coordinates the appropriate strategy and the necessary interaction with authorities, ethics committees, or Notified Bodies.
The regulatory strategy significantly influences study design, endpoint selection, and the marketing authorization pathway. Early consultations with authorities—so-called Scientific Advice Meetings at the EMA or national authorities such as the BfArM—help clarify open questions before costly investments are made. RA is therefore not just a compliance function, but a strategic lever for the entire product development process.
Typical tasks throughout the product lifecycle
Regulatory Affairs accompanies the entire lifecycle of a product—from the preclinical phase to withdrawal from the market. Typical tasks include:
- Regulatory Strategy: Selection of the appropriate marketing authorization pathway (centralized, decentralized, or national procedure), classification, and definition of a realistic development timeline.
- Communication with Authorities: Preparation and moderation of Scientific Advice Meetings as well as the structured response to authority questions (Day 80/120/150 questions in the centralized procedure).
- Documentation and Dossiers: Preparation, maintenance, and submission of modules in the electronic Common Technical Document (eCTD) or technical documentation according to MDR/IVDR.
- Change Management: Assessment of regulatory impact for CMC changes, new indications, label updates, or manufacturing changes in accordance with Good Manufacturing Practice.
- Post-Marketing/Compliance: Support for Periodic Safety Update Reports (PSUR), Risk Management Plans (RMP), and other pharmacovigilance requirements.
- Product Labeling: Review and approval of Summary of Product Characteristics (SmPC), Package Information Leaflet (PIL), and labeling in accordance with regulatory requirements.
Regulatory Affairs in clinical trials (EU focus)
In clinical trials, Regulatory Affairs ensures that filings, approvals, and submissions in the EU are correctly implemented. Under the EU Regulation CTR 536/2014, applications for medicinal product studies are submitted via the Clinical Trials Information System (CTIS). RA typically coordinates the preparation of submission documents, the management of queries, and coordination with the sponsor, CRO, trial sites, and the Principal Investigator.
Important documents and topics in this environment include the Clinical Trial Protocol (CTP), the Investigational Medicinal Product Dossier (IMPD), and the Investigator’s Brochure. Requirements from Good Clinical Practice (especially ICH E6(R3)) also shape regulatorily sound implementation. The transition from the old Directive 2001/20/EC to the new CTR regime has fundamentally changed RA processes in many organizations: CTIS expertise and structured submission management are essential today.
Furthermore, Registered Trials in the EU are transparently accessible via EudraCT and, in the future, primarily via CTIS. RA is responsible for ensuring that these transparency obligations are met on time—including the publication of study results within the specified timeframe.
Success factors, medical devices, and the Right-first-time approach
For medical devices, Regulatory Affairs plays a central role in classification, conformity assessment, and the preparation of technical documentation. Under the EU MDR 2017/745, the Clinical Evaluation Report (CER) and—depending on the risk class—Post-Market Clinical Follow-up (PMCF) are essential. Here, RA works closely with Clinical Affairs, Quality Management, and—if required—a Notified Body. A key difference from medicinal products: there is no centralized regulatory approval process at the EU level for medical devices; conformity assessment is carried out by a Notified Body, while market surveillance lies with national authorities.
Regulatory Affairs is only as good as the database on which decisions are made. Therefore, close cooperation with Clinical Data Management, Medical Writing, and Quality Assurance is crucial. A “Right-first-time” approach—complete, consistent, and traceable dossiers—reduces queries and significantly accelerates the time-to-approval.
Within mediconomics projects, it is repeatedly shown that organizations that involve RA early and continuously achieve more stable timelines and lower regulatory risks. This also includes systematic Regulatory Intelligence Management, which proactively tracks changes in the regulatory environment (new EMA guidelines, ICH updates, court rulings) and incorporates them into the strategy.
Modern RA teams also use digital tools for eCTD compilation, submission tracking, and Regulatory Information Management (RIM) to meet growing demands for efficiency and transparency. The ability to manage and evaluate regulatory data in a structured manner is becoming increasingly important in the context of EU health data spaces and increasingly digital authority processes.
Frequently Asked Questions (FAQ)
Is Regulatory Affairs the same as Quality Assurance?
No. Quality Assurance (QA) focuses on quality management systems, processes, and internal compliance (e.g., audits, SOPs, GMP requirements). Regulatory Affairs focuses on regulatory strategies, submissions, and direct interaction with authorities. In practice, both functions work closely together but pursue different primary goals and methods.
When should Regulatory Affairs be involved in a development project?
As early as possible—ideally during preclinical or early clinical planning. Early regulatory decisions directly influence study design, endpoints, dossier structure, and the subsequent marketing authorization pathway. Retroactive corrections are time-consuming and expensive.
Which documents are particularly RA-relevant?
Typical key RA documents include eCTD modules (Modules 1–5), the IMPD, the Investigator’s Brochure, the Clinical Trial Protocol, the Clinical Study Report, and, for medical devices, the technical documentation including the CER and PMCF plan. Additionally, there is correspondence with authorities and minutes from Scientific Advice Meetings.
Regulatory References
- EU Clinical Trials Regulation (CTR) 536/2014
- EU Medical Device Regulation (MDR) 2017/745
- EU In Vitro Diagnostic Regulation (IVDR) 2017/746
- ICH E6(R3) Guideline for Good Clinical Practice
- EMA Guideline on Scientific Advice and Protocol Assistance (EMA/CHMP/SAP)
- EudraLex Volume 2: Pharmaceutical Legislation on Notice to Applicants